Your CDx Partner from Translational Research to Global Commercialization

NGS for Pharma

Accelerate access to treatment

Our vision is to democratize NGS globally and bring genomic testing closer to patients.

Our highly automated and end-to-end solutions enable a broad spectrum of laboratories to provide genomic profiling with rapid turnaround time, bringing precision oncology to more patients everywhere.

 

 

Why is Oncomine Solutions the preferred choice for pharma?

why-oncomine-icons-ngs-2

Innovative NGS technology combines speed and automation to empower more labs to conduct testing, even with small and challenging samples.

 

why-oncomine-icons-partner-2

Exceptional track record and capability of CDx co-development through regulatory approval and commercialization, providing more patients to access therapies.

 

why-oncomine-icons-globe-2

Globally distributed NGS CDx solution: commercially available and reimbursed by government and private payors in the US, EU, Asia, and the Middle East, accelerating patient access to new therapies through local testing.

Oncomine
NGS Technology

Our technology solves the challenges of routine biomarker testing in clinical oncology. 

  • Shorter turnaround times provide clinicians with timely results for more informed treatment decisions​
  • Automated workflows reduce labor time and operational costs​
  • Low sample input requirements enables more samples to be tested successfully so more patients can get actionable results

 

Oncomine NGS CDx Solutions

Oncomine Dx Target Test was the first distributable NGS-based CDx test approved in 2017.

It is now commercially available as a distributable test, which can be implemented in laboratories around the world.

Oncomine Dx Express Test is a CE-IVD test that enables rapid NGS testing for clinically relevant biomarkers, delivering results in as little as 24 hours.

 

  Oncomine Dx Target Test* Oncomine Dx Express Test (CE-IVD)**
Sample Type FFPE FFPE, plasma
Number of Genes 46 (EU & Japan), 23 (US) 46
Nucleic Acid Type DNA and RNA DNA, RNA, and cfTNA
Alteration Types Mutations and fusions​ Mutations, copy number variants, fusions​
Instrument PGM Dx Genexus Dx Integrated Sequencer (CE-IVD)
Workflow Manual Automated
Turnaround Time (Days)

4

1

Reimbursement Status Reimbursed in most countries launched In Development

Oncomine Dx Target Test CDx Indications

Companion Diagnostic News

Global Approvals and Commercialization

Oncomine Dx Target Test, is approved and reimbursed by government and commercial insurers in over 15 countries, covering more than 550 million lives globally.

CDx-coverage-icons-v2-4

11
CDx Approved

ALK
BRAF
EGFR mutations & deletions
EGFR insertions
ERBB2 (HER2) activating mutations
IDH1
MET exon 14 skip
ROS1
RET fusions
RET mutations
IDH1/2

CDx-coverage-icons-v2-3

14
Pharma Partners

AstraZeneca
Bayer
Blueprint Medicines
Boehringer Ingelheim
Chugai Pharmaceuticals
Daiichi Sankyo
Hengrui Therapeutics 
Janssen Oncology
Lilly Oncology
Novartis
Pfizer
Servier  
Pharmaceuticals
Spectrum           
Pharmaceuticals
Takeda    
Pharmaceuticals

CDx-coverage-icons-v2-2

19
Countries

Austria
Australia
Belgium
Canada
Denmark
Finland
France
Germany
Italy
Israel
Japan
Korea
Netherlands
Poland
Spain
Saudi
Switzerland
United Kingdom
United States

CDx-coverage-icons-v2

20
Therapies on Label

afatinib
alectinib
amivantamab-vmjw 
brigatinib
capmatinib
crizotinib
dabrafenib with trametinib 
dacomitinib
entrectinib
encorafenib
erlotinib
fam-trastuzumab-deruxtecan-nxki
gefitinib
ivosidenib 
lorlatinib
osimertinib
pralsetinib
selpercatinib
tepotinib
vorasidenib

Not all therapies are approved in all regions. Please refer to the intended use per country for details.

Have questions? Request a CDx consultation.

 

button_request-contact

 

*For In Vitro Diagnostic Use.

** For In Vitro Diagnostic Use. Not available in all countries including the United States.

Abbreviated Intended Use: The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high-throughput, parallel sequencing technology to detect single-nucleotide variants (SNVs), insertions, and deletions in 23 genes from DNA and fusions in ROS1 and RET from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non–small cell lung cancer (NSCLC), IDH1 R132 mutations from FFPE tumor tissue samples from patients with cholangiocarcinoma (CC) and RET SNVs, MNVs, and deletions from DNA isolated from FFPE tumor tissue samples from patients with medullary thyroid cancer (MTC), and RET fusions from RNA isolated from FFPE tumor tissue samples from patients with thyroid cancer (TC) using the Ion PGM Dx System.

Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology and the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions, and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. The Oncomine Dx Express Test also detects deletions, insertions and substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.